Your browser doesn't support javascript.
loading
Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma: A Translocation-Associated Sarcoma.
Doshi, Sahil D; Oza, Jay; Remotti, Helen; Remotti, Fabrizio; Moy, Matthew P; Schwartz, Gary K; Ingham, Matthew.
Affiliation
  • Doshi SD; Department of Medicine, Columbia University Irving Medical Center, New York, NY.
  • Oza J; Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY.
  • Remotti H; Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY.
  • Remotti F; Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY.
  • Moy MP; Department of Radiology, Columbia University Irving Medical Center, New York, NY.
  • Schwartz GK; Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY.
  • Ingham M; Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY.
JCO Precis Oncol ; 5: 1-5, 2021 11.
Article in En | MEDLINE | ID: mdl-34994591
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fibrosarcoma / Immune Checkpoint Inhibitors / Myxosarcoma Type of study: Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male Language: En Journal: JCO Precis Oncol Year: 2021 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fibrosarcoma / Immune Checkpoint Inhibitors / Myxosarcoma Type of study: Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male Language: En Journal: JCO Precis Oncol Year: 2021 Document type: Article